A high-growth biotech with approximately 69% revenue expansion and significant analyst-implied upside that is simultaneously running a deeply negative cash burn, trading in a confirmed downtrend below a declining 200-day average, and carrying 26% short interest — a high-risk, binary-outcome setup where execution consistency must improve before the risk/reward becomes actionable.
Thesis pillars
- Death Cross Confirmed Downtrend↑Improving
- Catastrophic Cash Burn Runway Risk→Stable
- High Short Interest Options Skepticism↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 12, 2026· older than 90 days
CRISPR Therapeutics AG (CRSP) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $49.99: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 5.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Negative price momentum.
CRISPR Therapeutics AG develops gene-editing therapies using CRISPR/Cas9 technology, with one approved product — CASGEVY for sickle cell disease and transfusion-dependent beta thalassemia — commercialized jointly with Vertex Pharmaceuticals. Revenue comes entirely from a 40%... Read more
Sell if holding. Engine safety override at $49.99: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 5.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Negative price momentum. Chart setup: RSI 49 mid-range, Bollinger mid-band. Score 5.1/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.40, earnings proximity 99d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
About CRISPR Therapeutics AG
About CRISPR Therapeutics AG
CASGEVY, the first approved CRISPR-based gene therapy, received marketing authorizations for sickle cell disease and transfusion-dependent beta thalassemia in the United States, EU, Great Britain, Canada, Switzerland, and six Middle Eastern countries by 2025 year-end. CRISPR Therapeutics AG holds a 40% economic interest in CASGEVY through its Vertex collaboration, but that revenue share was insufficient to cover the company's 40% share of program costs. Cash, equivalents, and marketable securities were approximately $1.975 billion at December 31, 2025, projected sufficient for at least 24 months.
Revenue flows from CRISPR Therapeutics' 40% share of CASGEVY net sales, which Vertex Pharmaceuticals leads in commercializing across approved markets targeting an estimated 60,000 patients with severe sickle cell disease or transfusion-dependent beta thalassemia in the U.S., Canada, Europe, and parts of the Middle East. Prior to 2025, annual CASGEVY program cost exposure was capped at $110.3 million under a deferral provision in the Vertex agreement; that provision expired at the start of 2025, raising the company's cost burden. Beyond hemoglobinopathies, CRISPR Therapeutics is advancing in vivo liver-editing candidates including CTX310 (Phase 1b for ANGPTL3) and CTX340 (for hypertension), a CAR T program featuring zugocabtagene geleucel in Phase 1/2 for autoimmune disease and hematologic malignancies, and an siRNA collaboration with Sirius Therapeutics entered in May 2025. Manufacturing for zugocabtagene geleucel is conducted at the company's internal GMP facility in Framingham, Massachusetts.
Show full overview
The company's near-term financial trajectory depends on whether CASGEVY commercial uptake can offset the expanded cost burden, and on whether CTX310 or zugocabtagene geleucel can advance to registrational trials. No in vivo gene-editing therapy had been approved in the U.S. or EU as of the 10-K date, subjecting CRISPR Therapeutics' in vivo programs to a novel regulatory pathway without established precedent. The 10-K discloses that CASGEVY program expenses are expected to exceed the company's 40% revenue share for the foreseeable future — a dynamic that, if uptake ramps slower than projected, could require additional capital before the 24-month runway expires.
See also: Healthcare · Biotechnology
From CRISPR Therapeutics AG's most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated Nov 3, 2026Recent Developments — CRISPR Therapeutics AG
Latest news
- NEWS Needham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target — benzinga Nov 3, 2026 positive
- NEWS CRISPR Therapeutics Says CASGEVY Q3 Revenue Of $99M Up 30% From Prior Quarter; More Than 750 Patients Have Initiated Tre — benzinga Nov 2, 2026 positive
- NEWS CRISPR Therapeutics Says FDA Granted RMAT Designations To CTX310 For Severe Hypertriglyceridemia And Elevated LDL Choles — benzinga Nov 2, 2026 positive
- NEWS CRISPR Therapeutics Q3 EPS $(1.15) Misses $(0.98) Estimate, Sales $12.669M Beat $10.495M Estimate — benzinga Nov 2, 2026 negative
- NEWS CRISPR Therapeutics Appoints Sivakesava Sakhamuri as Chief Technical Officer — fiscal.ai Nov 2, 2026 positive
Latest item Nov 3, 2026 · Generated 2026-11-04T11:59:35Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $49.99: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 5.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Negative price momentum. Chart setup: RSI 49 mid-range, Bollinger mid-band. Prior stop was $46.49. Score 5.1/10, moderate confidence.
Analyst target: $77.07 (+54.2% upside). Prior stop was $46.49. Stop-loss: $46.49.
Quality below floor (1.8 < 4.0); Value-trap signals (3/5): Revenue declining (-42.9% YoY), Margin compression (op margin -4043.8%), Negative free cash flow.
CRISPR Therapeutics AG trades at a P/E of N/A (forward -13.9). TrendMatrix value score: 9.0/10. Verdict: Sell.
29 analysts rate CRSP, with a consensus score of 3.8/5. 19 analysts publish price targets averaging $86.
What does CRISPR Therapeutics AG do?CRISPR Therapeutics AG develops gene-editing therapies using CRISPR/Cas9 technology, with one approved product —...
CRISPR Therapeutics AG develops gene-editing therapies using CRISPR/Cas9 technology, with one approved product — CASGEVY for sickle cell disease and transfusion-dependent beta thalassemia — commercialized jointly with Vertex Pharmaceuticals. Revenue comes entirely from a 40% share of CASGEVY product sales under the Vertex collaboration, which did not cover program expenses in 2025; cash, equivalents, and marketable securities were approximately $1.975 billion at December 31, 2025.